ENOV logo

Enovis Corporation Stock Price

NYSE:ENOV Community·US$1.8b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

ENOV Share Price Performance

US$31.37
-7.35 (-18.98%)
36.8% undervalued intrinsic discount
US$49.67
Fair Value
US$31.37
-7.35 (-18.98%)
36.8% undervalued intrinsic discount
US$49.67
Fair Value
Price US$31.37
AnalystConsensusTarget US$49.67
AnalystLowTarget US$33.00

ENOV Community Narratives

AnalystConsensusTarget·
Fair Value US$49.67 36.0% undervalued intrinsic discount

Next Generation Orthopedic Technology Will Transform Global Care

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·
Fair Value US$33 3.7% undervalued intrinsic discount

Delayed Launches And Integration Risks Will Restrain Orthopedics Despite Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent ENOV News & Updates

Enovis: Healthy Recon Trends Vs. Market Apathy

Aug 27

Enovis Corporation's (NYSE:ENOV) Shares Lagging The Industry But So Is The Business

Jul 21
Enovis Corporation's (NYSE:ENOV) Shares Lagging The Industry But So Is The Business

Enovis Corporation Key Details

US$2.2b

Revenue

US$869.6m

Cost of Revenue

US$1.3b

Gross Profit

US$2.1b

Other Expenses

-US$830.0m

Earnings

Last Reported Earnings
Jul 04, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-14.52
Gross Margin
60.28%
Net Profit Margin
-37.91%
Debt/Equity Ratio
54.0%

Enovis Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with mediocre balance sheet.

1 Risk
2 Rewards

About ENOV

Founded
1995
Employees
7367
CEO
Damien McDonald
WebsiteView website
www.enovis.com

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. Its Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. It distributes its products through independent distributors and directly under the ESAB and DJO brands. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
Over the last 7 days, the market has remained flat, with no particular sector making any big moves this week. As for the longer term, the market has risen 17% in the past 12 months. Earnings are forecast to grow by 15% annually. Market details ›